We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

ImmunoPrecise Antibodies Ltd (IPA) NPV

Sell:7.26 CAD Buy:7.38 CAD Change: 0.23 CAD (3.27%)
Market closed |  Prices as at close on 28 January 2022 | Switch to live prices |
Sell:7.26 CAD
Buy:7.38 CAD
Change: 0.23 CAD (3.27%)
Market closed |  Prices as at close on 28 January 2022 | Switch to live prices |
Sell:7.26 CAD
Buy:7.38 CAD
Change: 0.23 CAD (3.27%)
Market closed |  Prices as at close on 28 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ImmunoPrecise Antibodies Ltd. is a technology platform company that is engaged in the full-service therapeutic antibody discovery. The Company is focused on offering species-agnostic advancements, such as the B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program. Its geographical segments include United States of America, Canada and Europe. The Company’s Antibody Discovery offers design, immunization, characterization and optimization, and preclinical services. The Company offers mammalian protein expression and purification services as stand-alone or in combination after an antibody discovery project to produce the number of antibodies that need for further work. Its mammalian rPEx platform allows the production of all kinds of proteins, including difficult-to-express proteins, Fc-fusion proteins and bispecific antibodies.

Contact details

+1 (604) 8060626

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
137.95 million CAD
Shares in issue:
19.43 million
Life Sciences Tools & Services
Canadian Venture Exchange
Canadian dollars

Key personnel

  • Jennifer Bath
    President, Chief Executive Officer, Director
  • Lisa Helbling
    Chief Financial Officer
  • Ilse Roodink
    Chief Scientific Officer
  • Carla Dahl
    Vice President of Marketing
  • Barry Duplantis
    Vice President - Client Relations
  • Stefan Lang
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.